Conference
Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)
Authors
Lübbert M; Schmoor C; Berg T; Kruszewski M; Schittenhelm MM; Götze K; Pabst C; Kündgen A; Ma T; Frey A
Volume
140
Pagination
pp. 9087-9088
Publisher
American Society of Hematology
Publication Date
November 15, 2022
DOI
10.1182/blood-2022-159471
Conference proceedings
Blood
Issue
Supplement 1
ISSN
0006-4971